Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 13/20 | 0.88 |
| ▸ | CCR6 | P51684 | 7/20 | 0.63 |
| ▸ | CXCR1 | P25024 | 5/20 | 0.60 |
| ▸ | CCR7 | P32248 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706225 | 1.00 | CXCR2 (0.88) | CXCR2CCR6CXCR1CCR7 | |
| SCHEMBL1707013 | 1.00 | CXCR2 (0.88) | CXCR2CCR6CXCR1CCR7 | |
| SCHEMBL12086719 | 0.94 | CXCR2 (1.00) | CXCR2CCR6CXCR1CCR7 | |
| SCHEMBL12262520 | 0.89 | CXCR2 (0.93) | CXCR2CCR6CXCR1 | |
| SCHEMBL12087214 | 0.85 | CXCR2 (0.95) | CXCR2CCR6CXCR1 | |
| SCHEMBL12087261 | 0.85 | CXCR2 (1.00) | CXCR2CCR6CXCR1 | |
| SCHEMBL12086733 | 0.84 | CXCR2 (1.00) | CXCR2CCR6CXCR1 | |
| SCHEMBL12087229 | 0.84 | CXCR2 (1.00) | CXCR2CCR6CXCR1 | |
| SCHEMBL12262452 | 0.84 | CXCR2 (0.85) | CXCR2CCR6CXCR1CCR7 | |
| SCHEMBL1706371 | 0.81 | CXCR2 (0.74) | CXCR2CCR6CXCR1CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183281-B2 | CXC-chemokine receptor ligands | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | claimed |
| EP-2155670-B1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2012-04-18 | — | — | EP | claimed |
| US-20100125071-A1 | CXC-CHEMOKINE RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | claimed |
| EP-2155670-A1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | claimed |
| WO-2008148790-A1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | claimed |
| US-8183281-B2 | CXC-chemokine receptor ligands | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| EP-2155670-B1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| US-20100125071-A1 | CXC-CHEMOKINE RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125071-A1 | CXC-CHEMOKINE RECEPTOR LIGANDS | CXCR2, CXCR1, CX3CR1 | CXCR2 1/4885CCR6 20/4885CXCR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.